Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study.

Jin Ju Park Jacob Lee Yu Bin Seo Sun Hee Na

Published in: Infection & chemotherapy (2022)

The nirmatrelvir/ritonavir prescription rate was low, with more than fourth-fifths of non-prescriptions being due to patient refusal. Symptom resolution was faster, and no life-threatening side effects were reported. Accurate information about drug safety must be provided to patients to make informed decisions regarding nirmatrelvir/ritonavir treatment.

Keyphrases

coronavirus disease
end stage renal disease
antiretroviral therapy
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
case report
prognostic factors
emergency department
high resolution
patient reported
healthcare
single molecule
respiratory syndrome coronavirus